Atara Biotherapeutics, Inc. ATRA
Set alert
8.01 USD -0.52 -6.10%
At close · Oct 30
8.16 +0.15 +1.87%
After hours · Oct 30, 4:00 PM ET
7.72 Day range 8.53
4.18 52-week range 18.09
- YTD
- -55.72%
- 1 year
- -42.99%
- Open
- 8.53
- Prev close
- 8.53
- Mkt cap
- 80.40M
- Vol
- 29.96K
- Avg vol
- 41.58K
- EPS
- -1.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.72
- High
- 8.53
- Forward P/E
- -1.52
- Beta
- 0.49
- Short ratio
- 7.11
- Inst. own
- 50.82%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.80
- 200-d avg
- 11.70
- 1y target
- 16.33
2Y chart
Events in this range
- Nov 12, 2024Earnings: -2.93; estimate -3.77; surprise 22.28%
- Nov 13, 2024Rating: Canaccord Genuity · Buy → Buy
- Dec 20, 2024Rating: Rodman & Renshaw · — → Buy
Signals (97)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 4 weeks ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| RSI: Overbought | May 12, 2026 | 5 months ago |
| RSI: Overbought | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 2, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 12, 2026 | 7 months ago |
| RSI: Oversold | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| RSI: Oversold | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| RSI: Overbought | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| RSI: Overbought | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| RSI: Overbought | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| MACD: Buy Signal | May 27, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 4, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| RSI: Overbought | Jan 3, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
Key statistics
- Market cap
- 76.78M
- Enterprise value
- 87.50M
- Trailing P/E
- 0.00
- Forward P/E
- -1.52
- PEG ratio
- 0.00
- Price / sales
- 1.23
- Price / book
- 0.00
- EPS (TTM)
- -25.32
- Beta
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -290.20%
- Revenue (TTM)
- 62.39M
- Revenue growth
- 2892.70%
- Free cash flow
- -2.97M
- Total cash
- 35.29M
- Total debt
- 52.70M
- Return on equity
- 0.00%
- Shares outstanding
- 5.76M
- Short % of float
- 11.36%
- 50-day average
- 10.80
- 200-day average
- 11.70
Analyst view
Consensus: buy
Buy
Price target (mean) 16.33 +103.9% upside
Now 8.01
- Target (low)
- 10.00
- Target (mean)
- 16.33
- Target (high)
- 21.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.34.
Financials — quick view
ATRA Revenue — quarterly 630.00K
ATRA Net income — quarterly -4.83M
ATRA EPS — quarterly -0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -3.77 | -2.93 | +0.84 | +22.28% |
| Aug 12, 2024 | Jun 1, 2024 | -1.25 | -3.10 | -1.85 | -148.00% |
| May 9, 2024 | Mar 1, 2024 | -9.25 | -5.75 | +3.50 | +37.84% |
| Mar 28, 2024 | Dec 1, 2023 | -15.25 | -14.00 | +1.25 | +8.20% |
| Nov 1, 2023 | Sep 1, 2023 | -15.75 | -16.50 | -0.75 | -4.76% |
| Aug 8, 2023 | Jun 1, 2023 | -16.25 | -17.00 | -0.75 | -4.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Rodman & Renshaw | init | — | Buy |
| Nov 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 16, 2024 | Mizuho | up | Neutral | Outperform |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Jul 17, 2024 | Goldman Sachs | main | Sell | Sell |
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atarabio.com
News
Your note
Sign in to keep a note on ATRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FUST MATTHEW K. | Director | Stock Award(Grant) | Mar 27, 2024 | 259,000 |
| GALLAGHER CAROL GILTNER | Director | Stock Award(Grant) | Mar 27, 2024 | 629,608 |
| HEIDEN WILLIAM K | Director | Stock Award(Grant) | Mar 27, 2024 | 359,000 |
| HENRICH JILL | Officer | Sale | Nov 17, 2024 | 19,378 |
| HYLLENGREN ERIC J | Chief Operating Officer | Sale | Nov 17, 2024 | 23,392 |
| MALLIK AMEET | Director | Stock Award(Grant) | Mar 27, 2024 | 227,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 8.14% | 468,938 | 6.25M | Sep 29, 2024 |
| Redmile Group, LLC | 7.85% | 452,270 | 6.03M | Sep 29, 2024 |
| Citadel Advisors Llc | 4.52% | 260,480 | 3.47M | Sep 29, 2024 |
| Bank of America Corporation | 3.54% | 203,627 | 2.71M | Sep 29, 2024 |
| Vanguard Group Inc | 3.14% | 180,715 | 2.41M | Sep 29, 2024 |
| Millennium Management Llc | 3.06% | 176,053 | 2.35M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.09% | 120,258 | 1.60M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.95% | 54,473 | 726.13K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 25,277 | 336.94K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.43% | 24,599 | 327.90K | Aug 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 14,000 | 186.62K | Sep 29, 2024 |
| Variable Insurance Products Fd II-Disciplined Small Cap Portfolio | 0.17% | 9,631 | 128.38K | Sep 29, 2024 |